A phase II trial of vinflunine as monotherapy or in combination with trastuzumab as first-line treatment of metastatic breast cancer.

@article{Yardley2010API,
  title={A phase II trial of vinflunine as monotherapy or in combination with trastuzumab as first-line treatment of metastatic breast cancer.},
  author={Denise A Yardley and Michael J Mccleod and Fred J Schreiber and Patrick Murphy and Jeffrey W Patton and Dana S. Thompson and Mythili Shastry and Mark A. Rubin and Marianne K. Melnik and Howard A. Burris and John D Hainsworth},
  journal={Cancer investigation},
  year={2010},
  volume={28 9},
  pages={925-31}
}
We investigated the microtubulin inhibitor vinflunine—with trastuzumab in human epidermal growth factor receptor-2 (HER2)-positive patients—as first-line metastatic breast cancer therapy. HER2-negative patients received vinflunine on day 1; HER2-positive patients received vinflunine/trastuzumab every 21 days. Forty-eight patients in each treatment group were planned; the sponsor terminated the study early. Thirty-two evaluable patients (vinflunine, 11; vinflunine/trastuzumab, 21) were enrolled… CONTINUE READING
5 Citations
39 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 39 references

A review of the use of trastuzumab (herceptin) plus vinorelbine in metastatic breast cancer

  • A. Chan
  • Ann Oncol 2007,
  • 2007

Vinflunine in combination with trastuzumab for treatment of HER2-positive metastatic breast cancer (ASCO Meeting Abstracts)

  • R. Paridaens, H. Wildiers, +4 authors H. Roche
  • J Clin Oncol 2007,
  • 2007

Similar Papers

Loading similar papers…